Pancreatic cancer-cost for overtreatment with gemcitabine

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1146-1151

  Ansari, Daniel ^a   Tingstedt, Bobby ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; FATIGUE; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; CANCER CHEMOTHERAPY; CANCER PATIENT; CATHETER COMPLICATION; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE UTILIZATION; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MEDICAL RECORD REVIEW; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PATIENT CARE; PATIENT SELECTION; SWEDEN; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NUCLEOSIDE TRANSPORT PROTEINS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SWEDEN;

EID: 84880315622     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.744140     Document Type: Article

References (27)

1. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54: 385-7.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-20.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Sun C, Ansari D, Andersson R, W u D. D oes gemcitabinebased combination therapy improve the prognosis of unresectable pancreatic cancer? A meta-analysis of 26 randomized controlled clinical trials. World J Gastroenterol 2012; 18: 4944-58.
5. Ritzel MW, N g A M, Yao SY, Graham K, Loewen SK, Smith KM, et al. Recent molecular advances in studies of the concentrative Na - -dependent nucleoside transporter (CNT) family: Identifi cation and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol Membr Biol 2001; 18: 65-72.
6. Garcia-Manteiga J, Molina-Arcas M, Casado F J, Mazo A, Pastor-Anglada M. Nucleoside transporter profi les in human pancreatic cancer cells: Role of hCNT1 in 2 ', 2 -difl uorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-8.
7. Spratlin JMJ. H uman Equilibrative Nucleoside Transporter 1 (hENT1) in pancreatic adenocarcinoma: Towards individualized treatment decisions. Cancers 2010; 2: 11.
8. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fl uorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008; 299: 1019-26.
9. Farrell J J, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-95.
10. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-35.
11. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-9.
12. Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, et al. Immunohistochemical analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol 2012; 19(Suppl 3): S558-64.
13. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956-61.
14. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, et al. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scand J Gastroenterol 2009; 44: 782-6.
15. Bergman AM, Pinedo H M, Peters G J. Determinants of resistance to 2 ′, 2 ′ -difl uorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19-33.
16. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65: 9510-6.
17. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1: 371-6.
18. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-8.
19. Boeck S, Raponi M, Richardson B, Towne P, Isaacson J, Ranger Moore J, et al. Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma. J Clin Oncol 2012; 30(Suppl) :abstr 4041.
20. Raponi M, Boeck S, Richardson B, Towne P, Isaacson J, Ranger-Moore J, et al. Two-thirds of pancreatic ductal adenocarcinomas have low expression of hENT1 as determined by the SP120 rabbit monoclonal antibody immunohistochemistry test. World GI 2012 (abstract).
21. Bra att veta om sjuklön. N ational Social Insurance Offi ce, Sweden. Faktablad. [cited 2012 Feb 28]. Available from: Http://www.forsakringskassan.se
22. Tingstedt B, Isaksson J, Andersson R. Long-term follow-up and cost analysis following surgery for small bowel obstruction caused by intra-abdominal adhesions. Br J Surg. 2007; 94: 743-8.
23. Söd ra regionsvå r dsnäm nden. R egionala priser och ersä t tningar f ör s ödra sjukvǎ rdsregionen 2011. [cited 2012 Mar 6]. Available from http://www.skane.se/sv/Webbplatser/ Sodraregionvardsnamnden/
24. Elkin EB, Weinstein MC, Winer E P, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004; 22: 854-63.
25. Tingstedt B, Andersson E, Flink A, Bolin K, Lindgren B, Andersson R. Pancreatic cancer, healthcare cost, and loss of productivity: A register-based approach. World J Surg 2011; 35: 2298-305.
26. Farrell J J, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 2012; 12: 395-403.
27. Okazaki T, Javle M, Tanaka M, Abbruzzese J L, L i D. S ingle nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320-9.